Monte Rosa Therapeutics Preclinical Trial of Potential Breast Cancer Therapy Shows Less Toxicity, Tumor Regression

MT Newswires Live2024-12-11

Monte Rosa Therapeutics (GLUE) said Wednesday that data from a preclinical trial of its drug MRT-9643 as a potential treatment for HR-positive/HER2-negative breast cancer has superior selectivity relative to other clinical-stage cyclin-dependent kinase 2 inhibitors and induced robust downstream CDK2 pathway suppression.

MRT-9643 drove deep tumor regression in preclinical cellular models of HR-positive/HER2-negative breast cancer when combined with current standard of care therapies, the company said.

"Our results demonstrate that MRT-9643 is a highly selective oral CDK2 degrader that could potentially avoid many of the dose-limiting toxicities associated with less selective CDK2 inhibitors," Chief Scientific Officer Sharon Townson said.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment